Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for September 14, 2021

9/14/2021

 
Regulatory Update
 
The FDA accepted the BLA for tislelizumab to treat unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma and set a PDUFA date for 7/12/22.
 
Announced Research Updates
 
Sanofi announced that in the 37 week, 131 patient, Phase III, PEGASUS trial, treatment with rilzabrutinib did not increase the remission rate compared to placebo in patients with moderate-to-severe pemphigus.
 
AstraZeneca announced that in the 1,013 patient, Phase III, open-label, POSEIDON trial, patients treated with durvalumab, tremelimumab and platinum-based chemotherapy achieved OS of 14 months and PFS of 6.2 months compared to 11.7 months and 4.8 months with platinum-based chemotherapy alone in patients with metastatic non-squamous or squamous non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions. 
 
Lilly announced that in the BRUIN trial, treatment with pirtobrutinib resulted in an overall response rate of 52% in 61 MCL patients and 63% in 139 chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients.
 
AB Science announced that in the 60-month, 712 patient, Phase III, AB12003 trial, treatment with masitinib plus docetaxel did not improve progression free survival (PFS) compared to docetaxel alone in the overall population of patients with metastatic Castrate Refractory Prostate Cancer. PFS was increased with masitinib plus docetaxel in patients with an ALP of 250 IU/mL or <.
 
Published Research Updates
 
In a three-year, 6,861 patient, Phase III trial, three doses of RTS,S/AS01 in the first year, followed by a booster dose in year two and three resulted in 278 cases of malaria per 1000 person-years compared to 305 cases per 1000 person-years with sulphadoxine/pyrimethamine plus amodiaquine chemoprevention and 113 cases per 1000 person-years with the combination of vaccine and chemoprevention in children 5 to 17 months of age in sub-Saharan Africa.
 
J&J is discontinuing the 2,637 patient, Phase IIb, Imbokodo trial, when the primary analysis failed to find a reduction in the incidence of HIV infection with the J&J HIV vaccine in a population of young women in sub-Saharan Africa at high risk of acquiring HIV.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.